| Size | Price | |
|---|---|---|
| 100mg | ||
| Other Sizes |
| Targets |
No specific pharmacological target; it is a stable isotope-labeled analog of uracil, a naturally occurring pyrimidine derivative and one of the four nucleobases in RNA. It is used as a tracer in metabolic studies rather than as a drug targeting a specific protein.
|
|---|---|
| ln Vitro |
As a 13C-labeled uracil, it exhibits the same biological properties as unlabeled uracil, serving as a substrate for enzymes involved in pyrimidine metabolism such as dihydropyrimidine dehydrogenase. It is incorporated into RNA and used as a tracer to study nucleic acid metabolism and turnover.
|
| ln Vivo |
No specific in vivo activity; incorporated into RNA and used as a tracer in metabolic studies. Stable heavy isotopes have been incorporated into drug molecules largely as tracers for quantitation during drug development, including studies on absorption, distribution, metabolism, and excretion.
|
| Enzyme Assay |
No specific enzyme binding protocols. It is used as an internal standard for the quantification of uracil and its metabolites in biological samples by liquid chromatography-mass spectrometry (LC-MS/MS) or gas chromatography-mass spectrometry (GC-MS). A standard sample containing Uracil-13C is spiked into the biological matrix, and the 13C signal is used to quantify unlabeled uracil.
|
| Cell Assay |
(1) Seed cells in culture medium. (2) Add Uracil-13C (1-100 uM) to the culture medium for 0-72 hours. (3) Harvest cells, extract RNA or metabolites, and analyze incorporation of 13C into nucleosides, nucleotides, and RNA by LC-MS/MS or GC-MS. (4) Calculate metabolic flux using isotopic enrichment data.
|
| Animal Protocol |
(1) Administer Uracil-13C (10-100 mg/kg) to mice via oral gavage or IP injection. (2) Formulation: dissolve in saline or 0.5% methylcellulose. (3) Collect blood and tissues (liver, kidney, tumor) at predetermined time points (0.5, 1, 2, 4, 8, 24 h). (4) Extract metabolites and analyze 13C enrichment by LC-MS/MS or GC-MS. (5) Calculate pharmacokinetic parameters of uracil metabolism.
|
| ADME/Pharmacokinetics |
Stable isotope tracers are formulated in saline for IV injection or in 0.5% methylcellulose for oral gavage. The 13C label does not alter the PK properties of uracil, which in mice has a half-life of approximately 30-60 minutes, Cmax ~ 50-100 uM (PO, 100 mg/kg), and rapid clearance via urine. Uracil is a normal endogenous metabolite, so background correction is needed.
|
| Toxicity/Toxicokinetics |
Uracil-13C is considered non-toxic because uracil is a naturally occurring biomolecule. Acute toxicity studies in rodents show LD50 > 2000 mg/kg (PO). The 13C label is a stable, non-radioactive isotope with no additional toxicity. In vitro, CCK-8 assays in primary hepatocytes show no cytotoxicity at concentrations up to 10 mM. The compound is for research use only, not for human therapeutic use.
|
| References |
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
[2]. Pałasz A, et al. In search of uracil derivatives as bioactive agents. Uracils and fused uracils: Synthesis, biological activity and applications. Eur J Med Chem. 2015 Jun 5;97:582-611. |
| Additional Infomation |
Uracil-(2-13C) is a pyrimidinone compound and a (13)C modified compound. Uracil C-13 is being investigated in the clinical trial NCT01677338 (a Phase II study evaluating the preliminary performance of the C13-URA breath test kit in patients with dyspepsia).
Uracil-13C is a stable heavy isotope of uracil, a naturally occurring pyrimidine derivative found in RNA. The 13C labeling at the C2 position makes it a valuable internal standard for quantifying uracil and its metabolites in drug development, especially in pharmacokinetic and metabolic flux studies. It is not a drug and has not been approved by the FDA or EMA; it is strictly for laboratory research use only. |
| Molecular Formula |
C313CH4N2O2
|
|---|---|
| Molecular Weight |
113.08
|
| Exact Mass |
113.031
|
| CAS # |
35803-45-3
|
| Related CAS # |
Uracil;66-22-8
|
| PubChem CID |
10171240
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.322g/cm3
|
| Melting Point |
>300ºC (dec.)(lit.)
|
| Index of Refraction |
1.502
|
| LogP |
-1.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
161
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CN[13C](=O)NC1=O
|
| InChi Key |
ISAKRJDGNUQOIC-AZXPZELESA-N
|
| InChi Code |
InChI=1S/C4H4N2O2/c7-3-1-2-5-4(8)6-3/h1-2H,(H2,5,6,7,8)/i4+1
|
| Chemical Name |
(213C)1H-pyrimidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.8433 mL | 44.2165 mL | 88.4330 mL | |
| 5 mM | 1.7687 mL | 8.8433 mL | 17.6866 mL | |
| 10 mM | 0.8843 mL | 4.4216 mL | 8.8433 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT01677338
Conditions:Dyspeptic SubjectsProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
